Chronic Inflammation is Associated With Mental Illness

People with SLE can prevent flares of disease by avoiding sun exposure, not abruptly discontinuing medications, and monitoring their condition with the doctor.

Systemic lupus erythematosus (SLE) is an autoimmune disease. In this disease, the body's immune system mistakenly attacks healthy tissue. It can affect the skin, joints, kidneys, brain, and other organs. Up to 75 percent of patients with systemic lupus erythematosus (SLE) experience neuropsychiatric symptoms.

But so far, our understanding of the mechanisms underlying lupus' effects on the brain has remained murky. Now, new research from Boston Children's Hospital has shed light on the mystery and points to a potential new drug for protecting the brain from the neuropsychiatric effects of lupus and other central nervous system (CNS) diseases. The team has published its surprising findings in Nature.

Systemic Lupus Erythematosus (SLE) - Causes, Symptoms, Diagnosis and Treatment
Systemic Lupus Erythematosus (SLE) is an autoimmune disease that affects multiple organs like the joints, skin, kidney, heart, lungs, blood vessels and brain.

‘Nearly all people with lupus have a positive test for antinuclear antibody (ANA). However, having a positive ANA alone does not mean you have lupus.’

"In general, lupus patients commonly have a broad range of neuropsychiatric symptoms, including anxiety, depression, headaches, seizures, even psychosis," says Allison Bialas, PhD, first author on the study and a research fellow working in the lab of Michael Carroll, PhD, senior author on the study, who are part of the Boston Children's Program in Cellular and Molecular Medicine. "But their cause has not been clear -- for a long time it wasn't even appreciated that these were symptoms of the disease.

Collectively, lupus' neuropsychiatric symptoms are known as central nervous system (CNS) lupus. Carroll's team wondered if changes in the immune system in lupus patients were directly causing these symptoms from a pathological standpoint.

"How does chronic inflammation affect the brain?"

Genetic Clue to Development of Mouth Ulcers in Systemic Lupus Erythematosus
An association between a specific genetic pathway and the development of mouth ulcers in patients with systemic Lupus Erythematosus (SLE) has been observed.

Lupus, which affects at least 1.5 million Americans, causes the immune systems to attack the body's tissues and organs. This causes the body's white blood cells to release type 1 interferon-alpha, a small cytokine protein that acts as a systemic alarm, triggering a cascade of additional immune activity as it binds with receptors in different tissues.

Until now, however, these circulating cytokines were not thought to be able to cross the blood brain barrier, the highly-selective membrane that controls the transfer of materials between circulating blood and the central nervous system (CNS) fluids.

Air Pollution Exposure may Worsen Systemic Lupus Erythematosus in Children
An individual's exposure to air pollution may have a direct role in triggering disease activity as well as airway inflammation in children with SLE.

"There had not been any indication that type 1 interferon could get into the brain and set off immune responses there," says Carroll, who is also professor of pediatrics at Harvard Medical School.

So, working with a mouse model of lupus, it was quite unexpected when Carroll's team discovered that enough interferon-alpha did indeed appear to permeate the blood brain barrier to cause changes in the brain. Once across the barrier, it launched microglia -- the immune defense cells of the CNS -- into attack mode on the brain's neuronal synapses. This caused synapses to be lost in the frontal cortex.

"We've found a mechanism that directly links inflammation to mental illness," says Carroll. "This discovery has huge implications for a range of central nervous system diseases."

Blocking inflammation's effects on the brain

The team decided to see if they could reduce synapse loss by administering a drug that blocks interferon-alpha's receptor, called an anti-IFNAR.

Remarkably, they found that anti-IFNAR did seem to have neuro-protective effects in mice with lupus, preventing synapse loss when compared with mice who were not given the drug. What's more, they noticed that mice treated with anti-IFNAR had a reduction in behavioral signs associated with mental illnesses such as anxiety and cognitive defects.

Although further study is needed to determine exactly how interferon-alpha is crossing the blood brain barrier, the team's findings establish a basis for future clinical trials to investigate the effects of anti-IFNAR drugs on CNS lupus and other CNS diseases. One such anti-IFNAR, anifrolumab, is currently being evaluated in a phase 3 human clinical trial for treating other aspects of lupus.

"We've seen microglia dysfunction in other diseases like schizophrenia, and so now this allows us to connect lupus to other CNS diseases," says Bialas. "CNS lupus is not just an undefined cluster of neuropsychiatric symptoms, it's a real disease of the brain -- and it's something that we can potentially treat."

The implications go beyond lupus because inflammation underpins so many diseases and conditions, ranging from Alzheimer's to viral infection to chronic stress.

"Are we all losing synapses, to some varying degree?" Carroll suggests. His team plans to find out.

Source-Eurekalert